Intracameral Moxifloxacin for Prevention of Postcataract Endophthalmitis

• Status: Completed
• Trial end date: 2018-06-20
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study was to evaluate the efficacy and safety of the prophylactic effect of intracameral moxifloxacin for prevention of postcataract endophthalmitis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Universidade Federal de Pernambuco
• Treatments: Fluoroquinolones; Moxifloxacin; Norgestimate, ethinyl estradiol drug combination

Criteria

Inclusion Criteria:

• Diagnosis of visually significant cataract

Exclusion Criteria:

• Has known allergies to moxifloxacin

• Has significant ocular co-morbidities in one or both eyes which may include (but is not limited to): advanced glaucoma, advanced or active macular degeneration, Fuchs corneal dystrophy, prior corneal transplantation, advanced diabetic eye disease, history of retinal detachment or any patient that would require billing a complex cataract procedure for any reason

• Has a known history of a condition which causes an immuno-compromised host state